Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients

NCT02174432 is registered in ClinicalTrials.gov with Trevi Therapeutics as lead sponsor.

NCT NCT02174432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02174432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients
Lead sponsor
Trevi Therapeutics
Phase
Phase 2/3
Overall status
Completed
Start date
August 15, 2015
Completion date
September 3, 2017
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nodularis prurigo, prurigo, prurigo nodularis